PO-424 modulating hexokinase 2 (HK2) as a novel approach to target metabolic immuno-oncology

ESMO Open - Tập 3 - Trang A396-A397 - 2018
V. Behar1, R. Yosef1, E. Dor-On1, N. Amsalem1, Y. Horev1, O.M. Becker1
1Vidac Pharma, Discovery, Jerusalem, Israel